{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:54:43Z","timestamp":1775746483847,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sumitomo Dainippon Pharma fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jns.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T16:39:05Z","timestamp":1526575145000},"page":"5-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study"],"prefix":"10.1016","volume":"391","author":[{"given":"Ken","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Yanagihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehisa","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Takazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyokazu","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Mizumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jns.2018.05.013_bb0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.112.105379","article-title":"Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update","volume":"54","author":"Tatsch","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.jns.2018.05.013_bb0010","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"Bajaj","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"14","key":"10.1016\/j.jns.2018.05.013_bb0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/mds.25975","article-title":"Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts","volume":"29","author":"Kraemmer","year":"2014","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.jns.2018.05.013_bb0020","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1212\/WNL.0000000000003810","article-title":"Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease","volume":"88","author":"Saari","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.05.013_bb0025","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression","volume":"287","author":"Parkinson Study Group","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2018.05.013_bb0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00415-008-0849-z","article-title":"Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up","volume":"255","author":"Hesse","year":"2008","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2018.05.013_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157602","article-title":"N-acetyl cysteine may support dopamine neurons in Parkinson's disease: preliminary clinical and cell line data","volume":"11","author":"Monti","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jns.2018.05.013_bb0040","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25103","article-title":"Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies","volume":"82","author":"Kaasinen","year":"2017","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.05.013_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175424","article-title":"DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers","volume":"12","author":"Artzi","year":"2017","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.jns.2018.05.013_bb0050","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/jm00188a011","article-title":"Studies on 3-substituted 1.2-benzisoxazole derivatives 6: syntheses of 3- (sulfamoylmethyl)-1,2- benzisoxazole derivatives and their anticonvulsant activities","volume":"22","author":"Uno","year":"1979","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.jns.2018.05.013_bb0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson's disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"The Japan Zonisamide on PD study group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.05.013_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ncn3.179","article-title":"Preliminary study of zonisamide monotherapy in de novo patients with early Parkinson's disease","volume":"3","author":"Ikeda","year":"2015","journal-title":"Neurol Clin Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neures.2007.10.002","article-title":"Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation","volume":"60","author":"Asanuma","year":"2008","journal-title":"Neurosci. Res."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11011-010-9191-0","article-title":"Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice","volume":"25","author":"Yokoyama","year":"2010","journal-title":"Metab. Brain Dis."},{"issue":"1\u20132","key":"10.1016\/j.jns.2018.05.013_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12031-009-9181-z","article-title":"A novel anti-parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice","volume":"39","author":"Yano","year":"2009","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089076","article-title":"Zonisamide attenuates a-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease","volume":"9","author":"Arawaka","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jns.2018.05.013_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2018.05.013_bb0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","article-title":"Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study","volume":"72","author":"Pogarell","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2018.05.013_bb0105","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00259-006-0155-x","article-title":"Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio","volume":"33","author":"Tossici-Bolt","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/WNF.0b013e318211f945","article-title":"Single photon emission computed tomography striatal asymmetry index may predict dopaminergic responsiveness in Parkinson disease","volume":"34","author":"Contrafatto","year":"2011","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.jns.2018.05.013_bb0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/1381612043453180","article-title":"Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease","volume":"10","author":"Murata","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0920-1211(89)90041-7","article-title":"Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant","volume":"3","author":"Rock","year":"1989","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(87)90168-5","article-title":"Zonisamide enhances slow sodium inactivation in Myxicola","volume":"413","author":"Schauf","year":"1987","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-1211(92)90087-A","article-title":"Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex","volume":"12","author":"Suzuki","year":"1992","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","article-title":"Mechanisms of T-type calcium channel blockade by zonisamide","volume":"5","author":"Kito","year":"1996","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.jns.2018.05.013_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0014-2999(95)00202-V","article-title":"Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine","volume":"280","author":"Santiago","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"34","key":"10.1016\/j.jns.2018.05.013_bb0145","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","article-title":"Mechanism of toxicity in rotenone models of Parkinson's disease","volume":"23","author":"Sherer","year":"2003","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.expneurol.2009.11.002","article-title":"Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction","volume":"221","author":"Costa","year":"2010","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.expneurol.2010.04.017","article-title":"Zonisamide: aspects in neuroprotection","volume":"224","author":"Rosler","year":"2010","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.05.013_bb0160","first-page":"139","article-title":"Zonisamide treatment delays motor neuron degeneration and astrocyte proliferation in wobbler mice","volume":"1","author":"Hirayama","year":"2011","journal-title":"J Neurol Res."},{"issue":"11","key":"10.1016\/j.jns.2018.05.013_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142786","article-title":"H, et al., Zonisamide enhances neurite elongation of primary motor neurons and facilitates peripheral nerve regeneration in vitro and in a mouse model","volume":"10","author":"Yagi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2018.05.013_bb0170","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/IJN.S128705","article-title":"Zonisamide-loaded triblock copolymer nanomicelles as a novel drug delivery system for the treatment of acute spinal cord injury","volume":"12","author":"Li","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.jns.2018.05.013_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(97)00097-1","article-title":"The anticonvulsant zonisamide scavenges free radicals","volume":"30","author":"Mori","year":"1998","journal-title":"Epilepsy Res."},{"issue":"1\u20132","key":"10.1016\/j.jns.2018.05.013_bb0180","first-page":"23","article-title":"Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-d-aspartate and buthionine sulfoximine in the rat hippocampus","volume":"105","author":"Noda","year":"1999","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"issue":"9","key":"10.1016\/j.jns.2018.05.013_bb0185","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1528-1157.2000.tb00312.x","article-title":"Zonisamide reduces the increase in 8-hydroxy-2\u2032-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats","volume":"41","author":"Komatsu","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2018.05.013_bb0190","first-page":"49","article-title":"Efficacy of a novel drug, zonisamide, in the modulation of oxidative stress in Parkinson's disease. Neurol","volume":"5","author":"Hirayama","year":"2017","journal-title":"Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2018.05.013_bb0195","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J","article-title":"Effect of treatment with L-dopa\/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]\u03b2-CIT","volume":"14","author":"Innis","year":"1999","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jns.2018.05.013_bb0200","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bjp.0702389","article-title":"Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo","volume":"126","author":"Lamensdorf","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/WNF.0000000000000198","article-title":"Striatal dopamine transporter modulation after rotigotine: results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients","volume":"40","author":"Rossi","year":"2017","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.jns.2018.05.013_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.25220","article-title":"Neuropathological findings in benign tremulous parkinsonism","volume":"28","author":"Selikhova","year":"2013","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.jns.2018.05.013_bb0215","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00259-014-2796-5","article-title":"Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease","volume":"41","author":"Kaasinen","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"18","key":"10.1016\/j.jns.2018.05.013_bb0220","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1212\/WNL.0000000000000385","article-title":"Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease","volume":"82","author":"Hong","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2018.05.013_bb0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RLU.0000000000001430","article-title":"Comparison of dopamine transporter SPECT and 123I-MIBG myocardial scntigraphy to assess clinical severity in patients with Parkinson disease","volume":"42","author":"Okano","year":"2017","journal-title":"Clin. Nucl. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T21:21:59Z","timestamp":1661289719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18302260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"alternative-id":["S0022510X18302260"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.05.013","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}